Clinical Trials
Momenta Begins Pancreatic Cancer Trial
July 9, 2012 11:01 am | News | CommentsMomenta Pharmaceuticals has begun dosing in a Phase 1/2 clinical trial of M402 with gemcitabine in patients with advanced metastatic pancreatic cancer.
Lux Wraps Up Luveniq Trial Enrollment
July 9, 2012 10:54 am | News | CommentsLux Biosciences Inc. has completed patient enrollment in its Phase 3 clinical study using voclosporin for the treatment of non-infectious uveitis.
OBI-1 Stops Bleeds in Late-Stage Study
July 9, 2012 10:41 am | News | CommentsInspiration Biopharmaceuticals Inc. reported data on the efficacy of OBI-1for the treatment of serious bleeds in people with acquired hemophilia A.
StemCells Begins AMD Study
July 6, 2012 11:25 am | News | CommentsStemCells Inc. has initiated a Phase 1/2 clinical trial of HuCNS-SC in dry age-related macular degeneration, referred to as geographic atrophy.
Positive Data for HCV Candidates
July 6, 2012 11:20 am | News | CommentsIdenix Pharmaceuticals Inc. announced results from an ongoing Phase 2b study of IDX184 in combination with pegylated interferon and ribavirin.
FDA Approves AGS-003 SPA
July 6, 2012 11:15 am | News | CommentsArgos Therapeutics Inc. announced the approval of the revised special protocol assessment for its Phase 3 clinical study of AGS-003 for renal cell carcinoma.
EXPAND Trial Misses Primary Endpoint
July 6, 2012 11:04 am | News | CommentsMerck announced that a late-stage trial assessing Erbitux in combination with cisplatin and capecitabine for adenocarcinoma did not meet its primary endpoint.
Kappaproct Reduces Need for Colectomy
July 3, 2012 10:42 am | News | CommentsInDex Pharmaceuticals announced the publication of positive data from the company's compassionate use program with its lead compound Kappaproct.
e-Therapeutics Begins Cancer Trial
July 2, 2012 11:18 am | News | Commentse-Therapeutics plc has started a Phase 1 clinical trial of ETS2101 as a cancer treatment, enrolling patients with primary brain cancer or cancer that has spread to the brain.
NOXXON Begins Dosing in NOX-E36 Study
July 2, 2012 11:13 am | News | CommentsNOXXON Pharma has treated the first patient in a Phase 2a clinical trial of its anti-CCL2/MCP-1 Spiegelmer NOX-E36 in patients with diabetic nephropathy.
Infinity Advancing IPI-145 Development
June 28, 2012 4:58 pm | News | CommentsInfinity plans to initiate a Phase 2 trial of IPI-145 in patients with asthma, as well as a Phase 2 trial of IPI-145 in patients with rheumatoid arthritis in the second half of 2012.
Blisibimod Flunks Latest Trial
June 28, 2012 4:51 pm | News | CommentsAnthera Pharmaceuticals Inc. said its experimental lupus treatment blisibimod failed in a clinical trial, and changed its development plans for the drug.
ProtAffin Begins PA401 Study
June 28, 2012 11:32 am | News | CommentsProtAffin AG announced that it has started dosing healthy volunteers in a Phase 1 clinical trial with its investigational anti-inflammatory, PA401.
Chinese Regulators OK Voclosporin Trial
June 28, 2012 11:29 am | News | Comments3SBio Inc. has received approval from the State Food and Drug Administration to conduct a multi-center Phase 3 trial of voclosporin in China.
Positive Results in Diclofenac Study
June 28, 2012 11:21 am | News | CommentsIroko Pharmaceuticals announced Phase 3 study results showing patients treated with diclofenac experienced significant pain relief post-surgery compared with placebo.
Ifanserin Falls in Late-Stage Testing
June 26, 2012 10:55 am | News | CommentsVentrus Biosciences Inc. announced that its most advanced drug failed in two late-stage clinical trials. Ventrus said ifanserin did not work better than a placebo.
More Potential for Web-based Clinical Trial Document Exchange
June 25, 2012 8:59 am | News | CommentsThe 2012 IntraLinks Global Investigator Site Survey revealed an increased prevalence in the use of online tools from 2011 to 2012, but that there is a significant opportunity for investigator sites to improve efficiency through web-based solutions for clinical trial exchange.
MRN Incorporating Digital Pens
June 22, 2012 4:59 pm | News | CommentsMedical Research Network has unveiled the deployment of its new patient scheduling tool to manage, report, and track clinical trial projects in real time.
TT-401 Shows Promising Safety Data
June 22, 2012 3:34 pm | News | CommentsTransition Therapeutics announced that TT-401, a type 2 diabetes drug, showed an acceptable safety profile in non-diabetic obese subjects in a Phase 1 study.
FDA Approves Genta Study Design
June 22, 2012 2:12 pm | News | CommentsGenta has has reached an agreement with the U.S. Food and Drug Administration under its SPA process for a proposed Phase 3 trial of oral tesetaxel.
Perjeta Lengthens Overall Survival Time
June 22, 2012 10:49 am | News | CommentsGenentech announced that patients with HER2-positive metastatic breast cancer lived significantly longer when treated with the combination of Perjeta, Herceptin, and docetaxel.
UW Enrolling for Leukemia Study
June 21, 2012 11:22 am | News | CommentsThe University of Washington has begun enrolling patients in a Phase 2 study testing Cell Therapeutics' tosedostat in elderly patients with acute myeloid leukemia.
Huntington's Trial Completes Enrollment
June 21, 2012 11:16 am | News | CommentsRaptor Pharmaceutical Corp. has finished enrollment for its Phase 2/3 clinical trial of RP103 for the potential treatment of Huntington's disease.
Strong Data Boosts Idenix Treatment
June 21, 2012 10:56 am | News | CommentsHepatitis C drug developer Idenix Pharmaceuticals Inc. has reported promising results from a mid-stage study of a potential treatment.
Portola Moves PRT4445 Forward
June 19, 2012 11:35 am | News | CommentsPortola Pharmaceuticals Inc. announced enrollment of subjects in the second cohort of its Phase 1 study of PRT4445, a universal Factor Xa inhibitor antidote in clinical development.
